Key result
SGLT2 inhibitors reduce adverse cardiovascular outcomes in patients with type 2 diabetes.
Why the study?
Large-scale cardiovascular safety trials of new glucose-lowering drugs unexpectedly demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes, warranting a summary of recent trial findings, clinical implications, and ongoing research.
Do sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes in patients with type 2 diabetes mellitus?
Do sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes in patients with type 2 diabetes mellitus?
This narrative review summarizes clinical trial evidence showing that SGLT2 inhibitors reduce adverse cardiovascular outcomes in patients with type 2 diabetes mellitus and discusses future research directions.
May support SGLT2 inhibitor use for cardiorenal protection; extends prior data but leaves optimal application open pending larger trials.
Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research.
No takes yet. Share an insight, caveat, or question.
Zelniker et al. (2020) conducted a review in Type 2 diabetes mellitus. Sodium-glucose cotransporter 2 inhibitors was evaluated on Adverse cardiovascular outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: